• Mydecine participated in this year’s Annual Roth Conference, the Oppenheimer & Co. Annual Healthcare Conference, and will be at the upcoming Maxim Group’s Virtual Growth Conference
• These conferences represent an opportunity for the company to share its R&D pipeline, patent strategies and ongoing clinical trials
• Mydecine’s management has optimism for the future, as it taps into the growing psychedelics therapeutics and smoking cessation markets

Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) has been at the forefront of developing novel psychedelic and non-psychedelic molecules for medical use. Its research and development efforts have focused on compounds that can enable safer and more effective treatments for patients dealing with conditions with unmet needs in mental health and addiction disorders. Since its inception back in 2020, the company has made significant strides, not just in its research but also in its clinical trials. So far, it is the leading and only company in the industry that has an ongoing industry-sponsored clinical trial assessing psilocybin for nicotine addiction. Additionally, it is also pursuing other indications that include but are not limited to PTSD and anxiety. Mydecine got to share these advancements at this year’s Annual Roth Conference, the Oppenheimer & Co. Annual Healthcare Conference as well as Maxim Group’s Virtual Growth Conference. It also walked attendants through its R&D pipeline and patent strategies. The Roth Conference is renowned for its in-person experiences. Their March 2022 conference in Orange Country, California, let over 5,100 attendees in on Mydecine’s operations, providing one-on-one meetings with its management (https://ibn.fm/JG1TS). The 32^nd Oppenheimer & Co. Annual Healthcare Conference, also in March 2022, provided investors with an opportunity to interact with public and private healthcare companies in the healthcare industry, including Mydecine. The conference’s goal was to showcase nearly 300 companies that will likely shape the industry for the next decade to come. Mydecine stood out with its first- and second-generation novel therapeutics focusing on psychedelic compounds (https://ibn.fm/AoVdf). The other March 2022 conference is Maxim Group’s Virtual Growth Conference (March 28-30), offering attendees a unique opportunity to interact with executives and institutional investors. The virtual event features company presentations, roundtable discussions, fireside chats, and live Q&A with Chief Executive Officers (“CEOs”). In addition, it represents an opportunity for Mydecine’s management to share its progress so far and offer a glimpse into what it has planned for the future (https://ibn.fm/HL2uP). Mydecine, through its research, has positioned itself to capitalize on the opportunities in the industry, particularly with regards to psychedelic medicine for the treatment of mental health and addiction disorders. Already, the psychedelics therapeutics market is projected to be valued at $66.5 billion by 2030, representing a CAGR of 8.2% over the forecast period. Additionally, the smoking cessation market is expected to post a CAGR of 16.9% to reach $64 billion by 2026 (https://ibn.fm/EWDWA) Mydecine’s management is confident that with the investments made so far, coupled with the plans for the future, the company will capitalize on the industry’s growth, achieve significant progression and create value for its shareholders. For more information, visit the company’s website at www.Mydecine.com. NOTE TO INVESTORS: The latest news and updates relating to MYCOF are available in the company’s newsroom at https://ibn.fm/MYCOF

• Flora Growth is a cannabis cultivator and distributor operating a 100-hectare (about 247-acre) harvesting site called Cosechemos in central Colombia’s favorable growing climate
• Flora Growth has completed its first import of CBD-containing food and beverage products into the United States under its Mambe brand, thanks to Colombian regulatory changes in recent months allowing cannabis product exports
• Flora has filed licenses for 23 cannabinoid-infused food and beverage products with Colombia’s INVIMA food and drug regulatory body
• Imported Flora products will take advantage of the company’s U.S. distribution network customer database, which nearly doubled with last month’s acquisition of established CPG brand JustCBD
• JustCBD has over 300 products, 300,000 customers, and a network of over 14,000 stores across the United States and Flora’s operations will increase its capacity for international growth

The recently announced successful import of Mambe CBD-containing food and beverage products into the United States from Colombia marks a huge step for cannabis cultivator Flora Growth (NASDAQ: FLGC) in the company’s plans for becoming a global market distributor. Flora Growth’s 100-hectare (about 247-acre) Cosechemos cannabis cultivation site in central Colombia is key to its strategy, drawing on ideal conditions for cannabis production that include over 12.5 hours of natural sunlight 365 days a year, a labor force with substantial agricultural experience, and a government that is increasingly friendly to cannabis production and transportation as an outgrowth of years-long drug wars eradication efforts. Colombian President Ivan Duque green-lighted legalization of dried cannabis flower production and exports last July for food, textile and medicinal purposes, while resisting any effort to supply the recreational use market (https://ibn.fm/ne65L). Late last month, Duque signed a resolution that provides the necessary regulatory framework for cannabis product use and export to formalize the development (https://ibn.fm/cmhaL). “We are thrilled to be the first Colombian cannabis operator to capitalize on the law change President Duque signed into effect,” Flora Growth CEO Luis Merchan stated after announcing completion of the U.S. import of its products (https://ibn.fm/uwAR9). “Our team anticipated this regulatory update and has been laying the necessary foundation to expand this new supply chain pathway allowing Flora to quickly bring our diverse product portfolio and low-cost cannabis inputs to new high-growth international markets.” Flora has filed licenses for 23 cannabinoid-infused food and beverage products with Colombia’s food and drug regulatory body, the Instituto Nacional de Vigilancia de Medicamentos y Alimentos (INVIMA), including juices, sparkling seltzers, gummies, chocolates, ghee butter and healthy snack foods that prioritize natural ingredients and value-chain sustainability (https://ibn.fm/rHHVU). Flora anticipates expanding Cosechemos-sourced non-psychoactive flower and derivatives distribution during the coming months as a result of its acquisition of JustCBD, which was announced Feb. 28. JustCBD has an extensive network of over 14,000 stores with over 300,000 customers, boosting Flora’s overall database to more than 500,000 customers, and Flora states it expects JustCBD’s financial performance to immediately contribute to the company’s 2022 revenues and earnings. On March 2, the company announced that its Vessel brand had signed an agreement with JustCBD-affiliated Speedy Distribution that will introduce Vessel’s vape and dry herb products into traditional smoke shop channels (https://ibn.fm/WysA3). “We see this agreement as the first of many where we leverage JustCBD’s existing distribution network and Flora’s diverse product portfolio to amplify growth for our combined Company,” JustCBD CEO Hussein Rakine stated at the time. At the same time, the acquisition is expected to give JustCBD a boost for expansion from its U.S. base into international arenas where CBD products are permissible, including Germany, Mexico, and Colombia, the company states. For more information, visit the company’s website at www.FloraGrowth.com. NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://ibn.fm/FLGC

• The Bloombox Club subsidiary of PlantX now offers e-commerce platform services in Austria, the United States, the United Kingdom, and Germany for house plant home delivery services
• PlantX currently offers over 5,000 plant-based and vegan products to consumers online and around the world
• Educational material can be found online through the PlantX blog, YouTube Channel, and Recipe Guides

PlantX Life (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF), a one-stop-shop for plant-based items, through its wholly-owned subsidiary Bloomboxclub Limited, is announcing the launch of its Bloombox Club e-commerce platform expansion into Austria. The Bloombox Club broadens the scope of the PlantX subsidiary’s indoor plant selling business, operating in Austria, the United States, the United Kingdom, and Germany. “Our goal is to have the Austrian Bloombox Club e-commerce platform provide similar customer experiences across the brand. We are confident that this latest e-commerce platform will be successful,” PlantX Founder Sean Dollinger said, commenting on the Austrian launch (https://ibn.fm/0iIjo). Lorne Rapkin, CEO of PlantX, said the company was beyond pleased with the welcoming reception among its consumer base in Austria, as well as the immediate feedback received after the e-commerce site went live. “As we look ahead to the future, we are committed to capitalizing on this growth market opportunity by prioritizing customer satisfaction as we continue to share the Bloombox Club experience with our Austrian community.” The Bloombox Club e-commerce platform in Austria can be accessed at https://bloomboxclub.at/. PlantX and its Bloombox Club subsidiary promote a calmer, happier, and healthier atmosphere through the use of plants. There are scientific and medical benefits to purchasing plants for indoor use – which Bloombox Club is delivering right to the door of each consumer. One of the categories of plants for sale is “air-purifying” indoor plants. These types of plants can help remove chemicals and substances from the air around you, including carbon dioxide, formaldehyde, benzene molecules, nitrogen oxides, and sulfur oxides. As described in a PlantX blog, some of the best plants are Lucky Bamboo, Dragon Tree, Pothos, Spider Plant, Janet Craig, and Snake Plant (https://ibn.fm/ZEYsD). In addition to air-purifying plants, the Bloombox Club website also offers pet-friendly plants. Anyone with a pet knows how bringing something new into the home can pique their interest and, ultimately, their appetites. Keeping a pet-friendly plant in the home can reduce the number of vet visits due to ingesting a potentially fatal house plant. As of Q3 2021, PlantX offers over 5,000 products, all of which support the plant-based community. With categories including XGroceries, XBeverages, XFitness, XBeauty, XRecipes, and XGifts – the company is building a community that supports and increases the knowledge of plant-based living. PlantX offers multiple educational resources for site visitors and customers, including its podcasts, blog, and YouTube channel. The plant-based blog is a wealth of information for tips and tricks (and what it is like) to live a plant-based, vegan lifestyle. With titles like “Things That Should Be In The Vegan Pantry” and “Top 10 Indoor Plants You Can Easily Take Care Of”, readers can learn about living their best plant-based life while also filling the spaces in their homes with plants they aren’t likely to kill off. In addition to the blog, the PlantX website and YouTube Channel overflow with recipe options – making vegan dining much easier, even for a novice joining the community. No matter your plant-based living skill level, PlantX provides the options and the opportunities necessary to make living the lifestyle affordable, knowledgeable, and simple. PlantX puts all of the resources right at your fingertips. For more information, visit the company’s websites at www.PlantX.com, www.PlantX.ca, and https://investor.plantx.com/ and view PlantX for Plant-Based Investors. NOTE TO INVESTORS: The latest news and updates relating to PLTXF are available in the company’s newsroom at https://ibn.fm/PLTXF

• Company’s cloud-based, artificial intelligence (“AI”) platform, Pluaris(TM), is designed to read, organize and present mass amounts of information
• Nowigence has identified core challenges in the pursuit of knowledge that Pluaris is designed to solve
• A subscription-based SaaS product, the Pluaris platform can be used across different functions and sectors and can be adapted to each user’s needs

In a world where consuming tremendous amounts of text-based information is an essential part of life — both personally and professionally — Nowigence Inc. (NOWG) is working to make this task easy and enjoyable. The company’s cloud-based, artificial intelligence (“AI”) platform, Pluaris, is designed to digest, organize and present mass amounts of information. Gathering and retaining information today is difficult. Nowigence has identified core challenges in the pursuit of knowledge, including information overload, pervasive distractions, imperfect recall and information lost in communication. In spite of these challenges, notes Nowigence, “clients hire coding engineers, data scientists and project managers to scope the requirements of a specific use case in the form of technical specs, which is then converted into a solution. This consultancy-based approach is not scalable. From a customer’s perspective, it is expensive, time consuming and does not guarantee success” (https://ibn.fm/nOYd4). Looking to provide a more cost-effective, scalable option, Nowigence created Pluaris, a subscription-based SaaS product platform designed to be used across different functions and sectors as well as adapt to the needs of each user. Pluaris allows client-side users to work with the product from day one and have direct access to the database. “Most other cognitive information retrieval engines allow access from an intermediate interface where human-controlled quality screening have already ascertained the accuracy of the results,” explains the company. “Operating directly from the database provides two main benefits for users. The first is that the output is in real time or near real time, depending upon the frequency at which the data is refreshed. The second is that data anomalies are detected faster and are corrected in the database to prevent propagation of erroneous data. Our algorithms allow users to get to quality outputs faster than other competitive service offerings.” NOWG’s proprietary platform overcomes information overload by automatically scouring the web for news articles and other sources based on topics selected by the user; the platform then monitors drives and applications for updates. Pluaris also works 24/7 to turn narrative-intensive information into what Nowigence calls “scrollable intelligence,” ensuring the user can find and focus on the most valuable information. Pluaris overcomes imperfect recall by storing extracted intelligence in a searchable database and then facilitating search granularity to the level of detail a user is looking for. Additionally, the platform makes it possible to share the gathered relevant information within the platform. Simplifying learning is what Nowigence is all about. The company is committed to helping individuals, teams and enterprises quickly distill knowledge from massive amounts of textual data, both public and private. By integrating state-of-the-art data processing techniques in an intuitive interface at an affordable subscription price, Pluaris puts the power of data science into the hands of consumers. For more information, visit the company’s website at www.Nowigence.com. NOTE TO INVESTORS: The latest news and updates relating to Nowigence are available in the company’s newsroom at https://ibn.fm/NOW

• Fred Tio, the former senior creative director of Worldwide Marcom at Apple Inc., recently joined the Applied Magix advisory board
• Fred’s experience and advice is expected to be instrumental in helping Applied Magix grow
• The Applied Magix advisory board was created earlier this month with the aim of bringing together experienced and knowledgeable board members who, through consultation, will help the business grow and succeed

SPYR (OTCQB: SPYR), a technology company that, through its Applied Magix Inc. subsidiary, operates in the Internet of Things (“IoT”) Smart Home and Connected Car spaces, recently announced Fred Tio, the former senior creative director of Worldwide Marketing Communication (“Marcom”) at Apple Inc. (NASDAQ: AAPL), had joined the Applied Magix advisory board (https://ibn.fm/NUVTK). Commenting on the newest addition to the freshly formed advisory board, Applied Magix Founder and CEO Dr. Harald Zink expressed his pleasure at having Fred Tio as part of the team as his experience and advice would be instrumental in helping the business grow. Moving forward, it is expected that stakeholders and investors will see Fred’s influence on the development and expansion of the company’s ecosystem of Apple(R)-compatible products. SPYR announced the formation of the advisory board on March 1 with a clear goal. The board was intended to help Applied Magix deal with upcoming challenges by facilitating consultation with board members whose wealth of experience and knowledge is expected to be invaluable to Applied Magix’s success and continued growth (https://ibn.fm/LJxdM). “The advisory board concept will be of great help entering the coming phase of market share and revenue growth, especially as we further expand marketing and product development…. SPYR is looking forward to working with such distinguished and experienced executives who we have identified as potential members of the Applied Magix advisory board,” said SPYR CEO Tim Matula of the board’s formation. Applied Magix, which is in the business of developing and reselling Apple-ecosystem-compatible products, has been years in the making. “Several years ago, Applied Magix started taking shape when I had ideas for several brilliant products, and found that nobody was making them – and thus decided that it was time for a new company dedicated to making, once again, insanely great products,” explained Dr. Zink in his recent contribution to the ongoing “Meet Applied Magix” series (https://ibn.fm/nCVE6). Dr. Zink further explained that “The name for Applied Magix came out an old Apple II product company called ‘Applied Engineering,’ and a quote from Arthur C. Clarke that ‘any sufficiently advanced technology is indistinguishable from magic’ – and thus, Applied Magix was born.” Applied Magix holds its Apple Developer License as part of Apple’s Developer Program. The company sources best-in-class white-label HomeKit products and accessories from manufacturers, brands them, and then sells them. It also offers support services, including software updates. In due course, however, Applied Magix intends to eventually develop, manufacture, and sell its own line of branded products based on the Apple HomeKit framework. In the meantime, though, Apple enthusiasts can choose from the growing selection of products available on the company’s website. For product information, please see the Applied Magix website at https://AppliedMagix.com, or specific product sites:

• MagixDrive Wireless CarPlay Adapter –  https://appliedmagix.com/MagixDriveBundle
• HomeKit Secure Video Camera with iCloud Storage – https://appliedmagix.com/HomeKitCamera
• Multipurpose Sensor with Alarm – https://appliedmagix.com/HomeKitAlarmSensor
• Environment and Motion Sensor – https://appliedmagix.com/HomeKitMotionSensor
• Window and Door Contact Sensor – https://appliedmagix.com/HomeKitContactSensor
• MagixBlock USB DataBlocker – https://appliedmagix.com/MagixBlock
• MagixCharge Dual USB-C Car Charger – https://appliedmagix.com/MagixCharge

For more information, visit the company’s website at www.Spyr.com. NOTE TO INVESTORS: The latest news and updates relating to SPYR are available in the company’s newsroom at https://ibn.fm/SPYR

• Mental health conditions affect millions of people globally, some of whom are resistant to existing treatments
• In the early 1990s, Yale researchers discovered that ketamine offered immediate relief to chronically depressed patients, and since then, the scientists have continually investigated the compound’s role in mental health treatment
• Delic’s subsidiary, Ketamine Wellness Centers, notes that ketamine is now extensively used for multiple treatment-resistant mental conditions, with patient outcomes showing its therapeutic effectiveness
• Delic hopes to reach millions of people suffering from various mental health conditions who have lost hope of finding effective, affordable treatments

The World Health Organization (“WHO”) reports that mental health conditions, including depression, bipolar disorder, anxiety, schizophrenia, dementia, developmental disorders, post-traumatic stress disorder (“PTSD”), and more, are on the rise worldwide. Data from the ten years to 2017 showed a 13% increase in mental health conditions and substance use disorders, with the former causing disability among patients – for one in five years (https://ibn.fm/5gZto). A 2017 study estimated that about 10.7% of the world population, or 792 million people, lived with a mental health disorder (https://ibn.fm/pSrvt). More specifically, depression, a common illness worldwide that affected 264 million people in 2017, currently affects about 280 million people globally. Anxiety disorders and bipolar disorder affected 284 million people and 46 million people, respectively, in 2017. Cumulatively, 970 million people had a mental or substance use disorder. Mental health conditions impact every sphere of patients’ lives, including school, work, personal relationships, and the ability to engage in social activities. And keeping in mind that some patients are resistant to existing treatments, the burden is compounded even further. Combined, depression and anxiety, the two most common mental illnesses, usurp US$1 trillion annually from the global economy. So, the developments ensuing from an early 1990s observation by Yale scientists that pediatric anesthetic ketamine offered immediate relief to chronically depressed patients provide much-needed reprieve. Since the discovery, Yale researchers have continually investigated ketamine’s role in mental health treatments. “In their research, [the Elizabeth Mears and House Jameson Professor of Psychiatry and Professor of Neurobiology Ronald] Duman and others show that in a series of steps, ketamine triggers release of neurotransmitter glutamate, which in turn stimulates growth of synapses. Research at Yale has shown that damage of these synaptic connections caused by chronic stress is rapidly reversed by a single dose of ketamine,” a 2012 Yale News article reads (https://ibn.fm/fk2Su). Building on the years of research into the use of ketamine as a treatment for depression, Yale scientists began investigating whether this compound could help patients suffering from severe PTSD. And according to Ketamine Wellness Centers (“KWC”), a wholly owned subsidiary of Delic Holdings (CSE: DELC) (OTCQB: DELCF), ketamine is now extensively utilized for treatment-resistant depression, anxiety, PTSD, suicidality, obsessive-compulsive disorder (“OCD”), PTSD, chronic and neuropathic pain, and anxious bipolar depression. Data provided by KWC, in fact, demonstrate that ketamine treatment has shown effectiveness of more than 50% among patients with borderline personality disorder, over 65% effectiveness in patients with depression and PTSD or anxiety, more than 76% effectiveness in patients with major depressive disorders, and over 80% effectiveness in patients with bipolar disorder (data available via Delic’s January 2022 investor deck at (https://ibn.fm/gYmWz). These successful outcomes are due to a carefully designed treatment approach wherein KWC’s skilled professionals with experience in ketamine therapy administer clinically controlled protocols to patients in therapeutic settings and offer medical supervision (https://ibn.fm/72CEh). Through KWC, Delic operates the largest, profitable chain of wellness clinics in the United States with 13 clinics across nine states with plans to open more state-of-the-art clinics in the ensuing 18 months. “We are thrilled to officially welcome the KWC team to the Delic family and cement our place as the largest network of treatment clinics in the U.S. With the addition of KWC, we can now reach millions of people suffering from various mental health conditions who have lost hope of finding effective, affordable treatments,” commented Delic Co-founder and CEO Matt Stang in a November 9 news release announcing the acquisition of KWC (https://ibn.fm/CaMqY). For more information, visit the company’s website at www.DelicCorp.com. NOTE TO INVESTORS: The latest news and updates relating to DELCF are available in the company’s newsroom at https://ibn.fm/DELCF

• More than 60% of American who suffer from mental health conditions want access to psychedelic options
• Growing number of cities, states looking at decriminalizing use of psychedelic medicine
• Cybin is working with world-class partners, internationally recognized scientists to create safe, effective therapeutics in the mental-health space

The awareness of psychedelics and the potential for treating an array of mental health diseases is growing, as evidenced by a recent survey reporting that 65% of affected Americans want access to psychedelics for potential treatment (https://ibn.fm/jIV2K). Those are numbers that Cybin (NEO: CYBN) (NYSE American: CYBN), a leading ethical biopharmaceutical company, is paying close attention to. “Respondents who self-reported that they suffer from a mental health condition say that psychedelic medicine, including ketamine, psilocybin mushrooms, and MDMA, should be made available to patients with treatment-resistant anxiety, depression, or PTSD,” a recent “Forbes” article reported. The article noted that the pandemic has skyrocketed the need for psychedelic wellness, with society reaching a “tipping point where the data and science regarding psychedelic therapies have become undeniable in treating a variety of serious conditions.” The article went on to explain that ketamine is legal in the United States for medical use; the substance is an FDA-approved anesthetic that can be prescribed for a myriad of ailments in a regulated setting by licensed clinicians. “Psilocybin, like cannabis, is still considered a Schedule 1 drug in the eyes of the federal government,” the article continued. “Therefore, its sale and use are illegal, despite some states and cities that have begun to decriminalize mushrooms. Beginning in 2019, psilocybin has been decriminalized in Denver, Oregon, and Santa Cruz. The state of California even has a measure on the 2022 ballot that would decriminalize psychedelic medicine in the state.” Clearly the tide is changing as popular opinion is swinging in favor of the powerful potential of psychedelics. A pioneer in the space, Cybin saw the writing on the wall long ago and has been actively working to establish itself as a leader in the psychedelic arena. Currently the company has three active drug programs targeting major depressive disorder, alcohol use disorder, anxiety disorders and neuroinflammation, as well as 50 novel compounds developed with more than 10 patent filings across three patent families (https://ibn.fm/VKH0T). In terms of investor interest, Cybin has raised $120 million to date to support its clinical trials and M&A strategy. In addition, the company is working with a network of world-class partners and internationally recognized scientists to create safe and effective therapeutics for patients to address a multitude of mental health issues. Headquartered in Canada and founded in 2019, Cybin is operational in the United States, the United Kingdom and Ireland. The company is focused on progressing psychedelics to therapeutics by engineering proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens for mental health disorders. For more information, visit the company’s website at www.Cybin.com. NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN

• The global surveillance video market is projected to hit $70 billion in revenue by 2026
• A violent crime occurs every 26.2 seconds and a property crime every 4.4 seconds in the United States
• Knightscope looks to tap into this existing opportunity with its Autonomous Security Robots (“ASRs”)
• With an annual subscription of just $4-$9 per hour, the company offers clients significant savings, in addition to increased security using the most advanced surveillance technology with unrivaled efficiency and effectiveness

The United States of America has invested heavily in equipping its troops with the latest and greatest technology. However, first responders have not been afforded the same level of attention and support. Today, it is estimated that there are over one million security guards in the country, over a million law enforcement professionals, 8000 private security firms, and over 19,000 law enforcement agencies. However, a violent crime occurs every 26.2 seconds, with property crimes occurring every 4.4 seconds. The job of providing security to people and businesses operating in 50 different states currently falls largely on a limited and costly base of human providers (https://ibn.fm/369jW). With these statistics, there is a need to revisit the security situation, with surveillance representing the critical first step in the overall security process. It is clear that the capacity with the current workforce to offer reliable security surveillance is severely wanting. However, there is a new and effective solution to this problem. Knightscope (NASDAQ: KSCP) is already blazing the trail in this sector. With its autonomous security solutions, this company is working towards solving critical human resource issues plaguing the security sector, a step toward realizing Knightscope’s stated mission of making the United States the safest country in the world. The company is a key developer and provider of Autonomous Security Robots (“ASRs”), technology that offers cost-effective 24/7/365 security in places where people study, visit, work, and live. These high-tech security patrolling robots are available to clients on a subscription basis, and its client list already comprises multiple Fortune 1000 companies, public institutions, and commercial business operations, among others. One of Knightscope’s primary selling points is the cost associated with the products and services it delivers. Its model features an annual subscription that ranges between $4 and $9 per hour. In addition, the service is all-inclusive, allowing clients to focus on their operations, knowing that the security aspect of their work is taken care of by Knightscope (https://ibn.fm/OQLaW). For comparison, human guarding costs an average of $17.5 an hour, bringing monthly expenses, for a single guard, to $12,775. With Knightscope, business owners’ security expenditure can range between $2,038 to $6,570, coupled with a 0% turnover rate and perks that include, but are not limited to, advanced detection capabilities and increased overall efficiency. With a single subscription, Knightscope clients enjoy deployment of the ASRs, the technology that comes both with the robots and the company’s security operations center for full communication and control, as well as after-sales services. Clients also get to enjoy unlimited software, firmware, and hardware upgrades, guaranteeing their security operations’ overall effectiveness and efficiency. It is projected that by 2026, the global surveillance video market will achieve $70 billion in revenue, representing a CAGR of 10.2% over the forecast period (2021-2026). This will be primarily attributed to the growing use of thermal cameras, smart city devices, and the Internet of Things (“IoT”). Knightscope recognizes this opportunity and is positioning itself to capitalize on this growth (https://ibn.fm/yrPiR). As a company pushing the limits of technology and artificial intelligence in the security space, Knightscope understands better than anybody the potential and the financial opportunity. The company is offering value not just to its clients but also to its shareholders while continuing to make the country safer. For more information, visit the company’s website at www.Knightscope.com. NOTE TO INVESTORS: The latest news and updates relating to KSCP are available in the company’s newsroom at https://ibn.fm/KSCP

• Metabolic disease cases rising globally, diseases include diabetes, dementia, cardiovascular conditions, stroke
• Companies in diagnostic space posting record revenues, double-digit YOY increases
• Nemaura Medical aims to disrupt the market with Mikobo program’s non-invasive sensor technology, companion mobile application and coaching programs
• Competitor devices use microneedles coated with enzymes and polymers that can cause discomfort, trauma, and skin changes

Clinical research reveals that volatile blood sugar fluctuations are a primary risk factor for rapidly rising cases of metabolic syndrome – a cluster of diseases that include diabetes, dementia, cardiovascular issues, and stroke. Abbott (NYSE: ABT), a global healthcare company targeting the space, recently posted 4Q21 record revenue of $1.02 billion for its FreeStyle Libre diagnostic product, a 35% YOY increase. Nemaura Medical (NASDAQ: NMRD), a medical technology company that develops affordable diagnostic and digital tools for chronic disease management, is strongly positioned to take a substantial market share with its recently launched Mikobo metabolic health and wellness program, offering a distinct competitive advantage with AI-powered monitoring devices that are non-invasive, easy to wear, and cost-effective. Sensors developed by Nemaura stand apart from competitor devices that employ microneedles coated with enzymes and polymers – some of which require insertion for up to five days. Besides causing discomfort upon insertion, users report trauma and bruising in addition to changes to the skin surface. In contrast, Nemaura Medical’s sugarBEAT(R) and proBEAT(TM) Continuous Glucose Monitors (“CGMs”) sit on the surface of the skin, are easy to apply, and can be worn comfortably without the need for extended periods of wear, providing real-time insights into a person’s state of metabolic health, dietary guidance, and exercise recommendations with the aim of improved long term health and wellness, potentially avoiding many of the chronic conditions that can arise from poor metabolic health. “A person’s response to sugar intake can influence a number of factors from appetite and body weight to sleep patterns, energy levels, and even mood, not to mention also being a considerable factor in chronic diseases like diabetes, heart disease and dementia,” said Nemaura CEO Dr. Faz Chowdhury. “With MiBoKo, we are able to extend our proprietary non-invasive device and sensor technology and interactive lifestyle and AI-based coaching programs beyond the traditional diabetes market and into an adjacent, yet separate, market application of consumer metabolic health.” According to Harvard Health, metabolic syndrome cases are rising – especially among women, young adults, Asian, and Hispanic populations. Besides causing multiple health issues among vulnerable groups, employers and insurers are burdened with rising health expenses. According to the International Diabetes Federation, estimates for diabetes expenses – one of many conditions caused by metabolic syndrome – topped $966 billion in 2021, a 316% increase from 15 years ago. “At Nemaura, we continue to look for the intersection of patient comfort and convenience through advanced and unique technology that addresses significant healthcare needs for large patient populations,” said Dr. Chowdhury. “We believe that MiBoKo offers insights into metabolic health in a user-friendly way unlike any other program on the market.” Nemaura’s novel technology could potentially help avoid or delay the onset of conditions such as diabetes, heart disease, and other conditions resulting from poor metabolic health. With a strong position at the intersection of the Type 2 diabetes, weight loss health tech, and prediabetic markets, Nemaura management strongly believes that MiBoKo will positively impact populations affected by diseases caused by poor blood sugar management. For more information, visit the company’s website at www.NemauraMedical.com. NOTE TO INVESTORS: The latest news and updates relating to NMRD are available in the company’s newsroom at https://ibn.fm/NMRD

• PlantX entered into an asset purchase agreement with Peter Rubi, LLC on December 12, 2021
• The purchase’s primary objective was to grow PlantX’s e-commerce enhancing strategy while leveraging Peter Rubi’s resources to increase revenue and market reach
• Following the purchase, PlantX has announced same-day delivery services for its products across Chicago and Plainfield, Illinois
• The company’s management is excited about the launch and what marks the beginning of other ambitious plans that PlantX has in store for this new year

On December 12, 2021, PlantX Life (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF), through its wholly-owned subsidiary, PlantX Midwest Inc., entered into an asset purchase agreement for the acquisition of all assets for Peter Rubi, LLC, along with the assumption of some of its liabilities. The purchase agreement was to the tune of $1.2 million in cash, in addition to 9,188,897 common shares in the authorized share structure of the company, valued at $0.2774 per share. The goal with the acquisition was to grow PlantX’s e-commerce enhancing strategy while leveraging Peter Rubi’s warehousing facilities, operational potential, extensive customer base, and plant-based merchandising expertise to increase revenue within the United States (https://ibn.fm/8jaeO). In what marks a significant move since this acquisition, PlantX has launched same-day delivery services for its products across Chicago and Plainfield, Illinois. The company plans to avail these services through third-party delivery apps, in addition to retail locations within these two cities, allowing for the deployment of its e-commerce marketing expertise to these specific locations (https://ibn.fm/vJneb). PlantX also announced its plans to use data from its e-commerce site and geo-targeted marketing to engage with the Illinois communities, ultimately bringing plant-based products to more customers and making the plant-based lifestyle accessible to all. “We see this new vertical as a way to increase our customer base through our retail locations while offering customers more choices in how they shop,” noted Lorne Rapkin, the Chief Executive Officer (“CEO”) of PlantX. “Allowing customers to order products for same-day delivery through third-party delivery apps is merging PlantX’s e-commerce strengths with the company’s newer venture into retail,” he added. The Chicago location has been rebranded as XMarket Uptown, and customers will now have access to a variety of plant-based brands and products, including, but not limited to, fresh produce, PlantX’s own ready-to-eat meals, and recipes. “Providing superior quality project and same-day services for our customers in Illinois is another step toward our strategic expansion plan,” reckoned Sean Dollinger, PlantX’s founder. While announcing Peter Rubi’s acquisition, Mr. Dollinger noted the company’s influential presence in the Chicagoland area. He further acknowledged how the purchase would give PlantX access to an amazing new community in and around the third largest city in the United States, all while solidifying its e-commerce market presence and impact in the Midwestern US. PlantX’s management is excited about Peter Rubi’s acquisition. These new developments regarding same-day delivery and the rebranding of the Chicago store are only the beginning of other ambitious plans that the company has in store for this new year. For more information, visit the company’s websites at www.PlantX.com. NOTE TO INVESTORS: The latest news and updates relating to PLTXF are available in the company’s newsroom at https://ibn.fm/PLTXF